Weight & metabolism

Tirzepatide

Zepbound, Mounjaro

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro). It is backed by large, multi-year clinical trial programs.

Key facts

  • Commonly discussed for: weight management and type 2 diabetes.
  • Evidence (A): SURMOUNT-1 randomized 2,539 adults and found 15% to 20.9% average weight loss at 72 weeks across doses versus 3.1% with placebo, within a larger phase 3 program.
  • FDA status: FDA-approved. FDA approved Zepbound for chronic weight management on November 8, 2023, and FDA reports the tirzepatide shortage is resolved.
  • Legitimate access: Rx brand.
  • Last reviewed: October 1, 2026.

Read the deep dives

Thinking about Tirzepatide?

Add it to your stack, then bring the list to a licensed provider. They can tell you whether it fits your health picture and what the legitimate options are. Peptiblox never sells peptides or links to sellers. Check the legal status tracker for the latest FDA changes.

Open my stack →

Sources